LTRN - Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multipl
LTRN - Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Story updates
12:06:51 PM UTC
SquawkNews
LTRN Lantern Pharma receives uspto notice of allowance for patent covering biomarker-guided treatment with lp-184 (zirdafulven) in multiple solid tumor cancers
LTRN - Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers